Related Experiment Video

Updated: Dec 28, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.2K

Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments

Anais Audebrand1, Laurent Désaubry1, Canan G Nebigil1

  • 1Laboratory of CardioOncology and Therapeutic Innovation, CNRS, Illkirch, France.

Frontiers in Cardiovascular Medicine
|February 11, 2020
PubMed

Insights

Novel anticancer drugs can cause heart problems. This study explores G protein coupled receptors (GPCRs) as targets for new cardioprotective drugs to prevent cancer treatment-induced heart failure.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Novel anticancer therapies improve cancer management but cause significant cardiac adverse effects, including heart failure.
  • Current cardioprotective strategies are insufficient and may even promote cancer.
  • G protein coupled receptors (GPCRs) are crucial drug targets, with 40% of existing drugs interacting with them.

Purpose of the Study:

  • To identify novel cardioprotective agents targeting GPCRs for managing cardiotoxicity induced by anticancer treatments.
  • To explore the potential of specific GPCRs in preventing or treating anticancer drug-induced heart failure.

Main Methods:

  • Review of newly identified cardioprotective agents that bind to specific GPCRs.
  • Discussion of GPCRs including those for adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin, and cannabidiol.

Main Results:

  • Identified several GPCRs (adrenalin, adenosine, melatonin, ghrelin, galanin, apelin, prokineticin, cannabidiol) as potential targets for cardioprotection.
  • Highlighted the need for further drug development targeting these GPCRs.

Conclusions:

  • GPCRs represent a promising therapeutic avenue for preventing and treating cardiotoxicity associated with anticancer therapies.
  • Targeting these GPCRs could lead to safer and more effective treatments for cancer patients experiencing heart failure.
Keywords:
GPCRsapelincannabidiolcardiotoxicitygalaninghrelinmelatoninprokineticin

More Related Videos

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers14:03

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers

Published on: March 24, 2023

2.3K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K